If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Perhaps the best-known hypothesis involving mercury and autism involves the use of the mercury-based compound thiomersal, a preservative that has been phased out from most childhood vaccinations in developed countries including the US and EU. There is no scientific evidence for a connection between thiomersal and autism, but parental concern about a relationship between thiomersal and vaccines led to decreasing rates of childhood immunizations and increasing likelihood of disease outbreaks in the 1990s. In 1999, the U.S. Public Health Service recommended that thiomersal be removed from childhood vaccines. By 2002, the flu vaccine was the only childhood vaccine using thiomersal. The removal of thiomersal did not decrease autism rates in any country that removed thiomersal from their childhood vaccines. A causal link between thiomersal and autism has been rejected by international scientific and medical professional bodies including the American Medical Association, the American Academy of Pediatrics, the American College of Medical Toxicology, the Canadian Paediatric Society, the U.S. National Academy of Sciences, the Food and Drug Administration, Centers for Disease Control and Prevention, the World Health Organization, the Public Health Agency of Canada, and the European Medicines Agency.
In August 2013 it was announced that the building would be sold on the open market, with a goal of realising offers above 100 million pounds. On 13 December 2014 the Ministry of Defence confirmed that the building would be sold to the Hinduja Group for an undisclosed amount. The building's sale was completed on 1 March 2016, for more than £350 million, on a 250-year lease, to the Hinduja Group (in partnership with OHL Developments) for conversion to a luxury hotel and residential apartments. The Hinduja Group and Raffles Hotels opened the hotel, named Raffles London at The OWO, in 2023.
In 1929, the cyclic nature of benzene was finally confirmed by the crystallographer Kathleen Lonsdale using X-ray diffraction methods. Using large crystals of hexamethylbenzene, a benzene derivative with the same core of six carbon atoms, Lonsdale obtained diffraction patterns. Through calculating more than thirty parameters, Lonsdale demonstrated that the benzene ring could not be anything but a flat hexagon, and provided accurate distances for all carbon-carbon bonds in the molecule.
Sources: en.wikipedia.org
Conditions in the predominant agricultural sector kept deteriorating between 1929 and 1939, which resulted in rural unrest and a progressive radicalization of the Polish peasant movement that became increasingly inclined toward militant anti-state activities. It was firmly repressed by the authorities. According to Norman Davies, the failures of the Sanation government (combined with the objective economic realities) caused a radicalization of the Polish masses by the end of the 1930s, but he warns against drawing parallels with the incomparably more oppressive Nazi Germany or the Stalinist Soviet Union.
== Nebraska Union controversy == The Runza restaurant operating in the Nebraska Union, the student union at the University of Nebraska–Lincoln (UNL), closed in 2018 after a decade of operating in the location. The Runza was outbid by a combination of two vendors (Steak 'n Shake and Chick-fil-A franchisees) bidding together. There was public outcry from the student body, as the runza is strongly identified as a Nebraskan dish, and students felt that it should be sold on UNL's campus. Runza eventually returned to the university in 2025.
=== 2020–present: Streaming ventures and resurgence === After a hiatus from lead roles, Morea returned to acting with a supporting role in Solo (2017) and later appeared in several streaming series, including Mentalhood (2020), Hostages (2020), Tandav (2021), and Kaun Banegi Shikharwati (2022). His performance in The Empire (2021) earned him an Indian Television Academy Award.in 2023, He appeared as an antagonist in Agent and Bandra. 2025, he played a significant role in the film Mere Husband Ki Biwi. He also appeared in the comedy sequel Housefull 5 as Bedi Dobriyal. The film features an ensemble cast including Akshay Kumar, Riteish Deshmukh, Abhishek Bachchan, Sanjay Dutt, Fardeen Khan, Jackie Shroff, Nargis Fakhri, Chitrangada Singh, Chunky Pandey and Johnny Lever. The film went on to become the second highest‑grossing installment in the Housefull franchise, making it the eight-biggest Hindi film of 2025. Indian entertainment publication Bollywood Hungama praised his performance as a "solid and strong," while Firstpost highlighted Morea's performance as a standout amidst the film's entertaining but sometimes overstretched storyline. The Times of India and other critics appreciated the humor but noted the film lacked consistently strong material overall. He also starred in the web series Rana Naidu and The Royals the same year. He appeared in Four More Shots Please.
Sources: en.wikipedia.org
November 1972); novelist, editor; placed 60th on the Independent on Sunday Pink List 2007; professor of creative writing at Royal Holloway, University of London; correspondent at the New Yorker; became a Fellow of the Royal Society of Literature in 2018; awards and nominations include John Llewellyn Rhys Prize, Somerset Maugham Award, Sunday Times 'Young Writer of the Year (shortlisted), London Arts New London Writers' Award, K. Blundell Trust Award, Le Prince Maurice Roman d'Amour Prize (shortlisted), Geoffrey Faber Memorial Prize (shortlisted), Man Booker Prize 2013 (longlisted) Baileys Women's Prize for Fiction 2014 (longlisted), Women's Prize for Fiction 2022 (longlisted for The Exhibitionist) Heather Mendick, Labour activist previously appointed as Jeremy Corbyn's Jewish liaison officer; former Hackney South constituency Labour party secretary, academic, previously Reader in Education at Brunel University and author of scholarly texts and monographs on educational theory, semantics, science, contemporary culture, ontology, ideology and epistemology, published by Routledge and McGraw Hill Education Farah Mendlesohn (b. 27 July 1968) is a British academic historian, best known for her writings on science fiction and fantasy. Gerard Menuhin, son of Yehudi Menuhin; grandson of leading anti-Zionist activist and scholar, Moshe Menuhin, and from the ancestral lineage of Rabbi Shneur Zalman of Liadi, the founder of Chabad Hassidism as well as Rabbi Levi Yitzchok of Berditchev.
== Awards and honors == 2014 – Silver Medal for "erma-Promp: Socks for xerosis treatment in diabetic feet, 42nd International Exhibition of Inventions of Geneva 2018 – Leader of Innovation prize, 11th International Invention and Innovation Show INTARG 2019 – Leadership Award (Grand Officer), British High Commission 2019 – Outstanding Professional Women Award, Federation of Business and Professional Women of Thailand 2021 – Gold Medal for "Sericin and chitosan cream for preventing and limiting the progressive of pressure sore", International Invention & Trade Expo 2024 – National Outstanding Researcher Award, NRCT
Widespread use Spironolactone — the first and most widely used member of this class Eplerenone — much more selective than spironolactone on target, but somewhat less potent and efficacious Uncommon use (to date) Canrenone and potassium canrenoate — very limited use Finerenone — nonsteroidal and more potent and selective than either eplerenone or spironolactone Some drugs also have antimineralocorticoid effects secondary to their main mechanism of actions. Examples include progesterone, drospirenone, gestodene, metribolone, and benidipine.
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.